Inspire Announces Poster Presentation at American Society of Cataract and Refractive Surgery Annual Symposium

DURHAM, N.C.--(BUSINESS WIRE)--Apr 4, 2008 - Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that Inspire scientists and collaborators will present information in a poster presentation at the American Society of Cataract and Refractive Surgery 2008 Symposium on April 4-9, 2008 in Chicago, IL.

The poster, "Comparison of AzaSite(R) and Azithromycin 1% for Bacterial Conjunctivitis" (C. Crean, J. Vittitow, R. Zink, L. Richards, R. Verhoeven, K. Powell and R.K. Brazzell), contains data from Inspire's post-marketing nonclinical research program with AzaSite. The data compares the ocular distribution of AzaSite, which is azithromycin formulated in DuraSite(R), to azithromycin delivered through an aqueous formulation and also demonstrates the tissue distribution and pharmacokinetics of azithromycin after the approved dosing regimen of AzaSite.

The poster presentation will be available on Inspire's website, www.inspirepharm.com, following the conference.

About Inspire

Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products in disease areas with significant commercial potential and unmet medical needs. Inspire employs a U.S. sales force for the promotion of AzaSite(R) (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis, Elestat(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and Restasis(R) (cyclosporine ophthalmic emulsion) 0.05% for dry eye. Inspire is focused on the therapeutic areas of ophthalmology and respiratory/allergy, and is developing products for dry eye, cystic fibrosis, allergic rhinitis and glaucoma. Elestat and Restasis are registered trademarks owned by Allergan, Inc. AzaSite is a registered trademark owned by InSite Vision Incorporated. For more information, visit www.inspirepharm.com.

Contact

Investor Contact:
Inspire Pharmaceuticals, Inc.
Jenny Kobin, 919-941-9777, ext. 219
VP, Investor Relations and Corporate Communications
or
Media Contact:
BMC Communications
Dan Budwick, 212-477-9007, ext. 14

Posted: April 2008

View comments

Hide
(web5)